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Ten patients suffering from chronic premature ventri-
cular complexes (>60/h) were treated orally in a double-
blind crossover study with encainide (SO 109three times
a day) and disopyramide (200 109 three times a day),
with five7 day study periods: survey, placebo, encainide
or disopyramide, washout placebo and disopyramide or
encainide. At the end of each 7 day period, a 12 lead
electrocardiogram, a 48 hour ambulatory electrocardio-
gram and a treadmill exercisetest were performed. Blood
levels of encainide and its metabolites and of disopyr-
amide were measured at the end of each treatment (steady
state). Drug efficacywas assessed by: 1) more than 80%
reduction in the number of premature ventricular com-
plexes per 24 hours, and 2) absence of ventricular
tachycardia.
Encainide was effective in four patients (complete
suppression of premature ventricular complexes) and
ineffective in five. One patient who showed a 92% re-
Patients with chronic premature ventricular complexes con-
stitute an ideal study group for the assessment of new an-
tiarrhythmic agents because such patients can tolerate pe-
riods of lack of treatment and placebo medication. Encainide,
a benzanilide derivative , has proved to be highly effective
in suppressing premature ventricular complexes and refrac-
tory recurrent ventricular tachycardia (l ,2). It is classified
as a type Ie antiarrhythmic drug . Substantial increases in
PR and QRS intervals occur during long-term encainide
therapy in a manner related to dose and plasma concentra-
tion. and few hemodynamic side effects are noted (2). In a
controlled trial in patients with premature ventricular com-
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duction in the number of premature ventricular com-
plexesdeveloped sustained ventricular tachycardia after
24 hours of treatment. Disopyramide was effective in
three patients (>80% reduction in the number of pre-
mature ventricular complexes) and ineffective in seven
patients. With encainide, the percent increase in PR,
QRS and QT interval duration was, respectively: 32.7
(p < 0.001), 30.8 (p < 0.001) and 10.6% (p < 0.01).
With disopyramide this increase was not significant. De-
spite the variability of drug blood levels, a relation be-
tween blood levels and suppression of premature ven-
tricular complexes on the 48 hour ambulatory
electrocardiogram was found with encainide, but not
with disopyramide. The ~ide effects observed for en-
cainide were visual disturbances and headache; for di-
sopyramide, they were headache, dryness of mouth and
dysuria.
(J Am CoU Cardiol 1985;5:1457-63)
plexes, encainide was shown to bemore effective than quini-
dine (3).
Disopyramide phosphate, which also demonstrates type
I antiarrhythmic action , is widely used in Europe for treat-
ment of ventricular arrhythmias (4- 6). Its pharmacologic
profile is similar to that of quinidine and procainamide and
it has been shown to have negative inotropic activity after
both intravenous and oral admini stration (7) .
In this study we compared the antiarrhythmic efficacy
and safety of oral preparations of encainide and disopyr-
amide in patients with chronic premature ventricular com-
plexes . To accomplish this, a double-blind crossover study
design was utilized .
Methods
Patients (Table 1). Ten patients (five men and five
women) aged 16 to 69 years entered the study. Each patient
0735-1097/85/$3 .30
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Table 1. Clinical Characteristics of 10Patients at Inclusion in the Study
Age (yr) Weight Underlying Other Medical Concurrent
Case &Sex (kg) Arrhythmia Heart Disease Conditions Medications
56M 59 PVC Myocardial Hiatal hernia; Acenocournarol
infarction + acrocyanosis
angina pectoris
2 40F 64 PVC + Angina pectoris + None Altizide +
nonsustained hypertension spironolactone;
VT lorazepam
3 28M 81 PVC None None None
4 57M 78 PVC + PAC Alcohol-associated Arthrosis Furosemide,
cardiomyopathy; potassium
mitral
regurgitation
5 16F 57 PVC + Arrhythmogenic None None
sustained VT dysplasia
6 19F 50 PVC None None None
7 31M 67 PVC None None None
8 32F 49 PVC None None None
9 53F 50 PVC + PAC None None None
)0 69M 79 PVC Myocardial infarction N0'1~ None
F = female; M = male; PAC = premature atrial complexes; PVC = premature ventricular complexes; VT = ventricular tachycardia.
had more than 60 premature ventricular complexes/hduring
an initial control study utilizing a 48 hour ambulatory elec-
trocardiogram. Patients with a recent myocardial infarction,
unstableangina, blood pressure above 180/120or lower than
90/60 mm Hg, uncontrolled congestive heart failure, sig-
nificant intracardiac conduction defect, atrioventricular block,
significanthepatic or renal impairment, QRS intervalgreater
than 0.12 second or PR interval greater than 0.3 second,
glaucoma, myasthenia gravis or symptomatic prostatic hy-
pertrophy were excluded from the study, as were pregnant
or nursing women. Informed consent was obtained from
each patient.
Trial design. A complete history and physical exami-
nation, 12 lead electrocardiogram, routine hematologic and
chemical tests and urinalysis were performedat the initiation
of the study. All previous antiarrthythmic agents were dis-
continued, and a baseline 48 hour ambulatory electrocar-
diogram was recorded after five half-lives of the previously
administered drug had elapsed. Eligible subjects were ran-
domly assigned to receive doses of disopyramide (200 mg
every 8 hours) or encainide (50 mg every 8 hours) for I
week.
After a I week period in which placebo was administered
every 8 hours, a 48 hour ambulatory electrocardiogramwas
recorded to confirm an average rate of premature ventricular
complexes greater than 60/h in all patients. Qualifying pa-
tients then received either encainide or disopyramide for 1
week. At the end of this second week, a 48 hour ambulatory
electrocardiogram was recorded. During the third week, all
the patients were again given placebo, after which a 48 hour
ambulatory electrocardiogram was again obtained. During
the fourth week, patients received the alternative drug reg-
imen, and a 48 hour ambulatory electrocardiogram was again
obtained at the end of this period. A 12 lead electrocardio-
gram, blood pressure and pulse rate were measured at each
visit.
A symptom-limited exercise test was performed on a mo-
tor-driven treadmill using the Bruce protocol under condi-
tions of maximal safety at the end of each week. The period
of exercise was analyzed separatelyon the ambulatory elec-
trocardiogram. Analysis focused on the frequency of pre-
mature ventricular complexes and runs during exercise in
comparison with their prevalence during the remainder of
the 24 hour electrocardiogram.
Patient compliance was confirmed by capsule count at
each visit. Randomization of initial treatment, alternate
crossover treatmentand placebo were prepared through cod-
ing and identical packaging of active drugs and placebo.
All patient conditions during therapy were reported.
Drug assessment. Patients were considered to be re-
sponders if the average frequency of premature ventricular
complexes was suppressed by 80% of the baseline value.
This level was chosen to reduce the influenceof spontaneous
variability. Episodes of ventricular tachycardia '(defined as
three or more consecutivepremature ventricular complexes)
were also recorded in patientsduring baseline measurements
and during each treatment sequence. Absence of total
suppression of ventricular tachycardia was considered to be
a drug failure. Ventricular tachycardia was defined as sus-
tained if it lasted 30 seconds or longer. Nonsustained ven-
tricular tachycardiawasdefinedas any event of 10sequential
complexes that lasted less than 30 seconds.
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Plasma concentration determination. Blood samples
(10 ml) were collected by direct venipuncture before the
morning intake, and 90 minutes after the intake on day 7
of weeks 2 and 4 (active drug weeks). After centrifugation,
the plasma samples were stored at - 200e until assayed.
Analysis was performed by high performance liquid chro-
matography, which detects both encainide and two of its
major metabolites, O-demethyl encainide (ODE) and 3-
methoxy-O-demethyl encainide (MODE). Disopyramide was
assayed using liquid chromatography after extraction from
plasma.
Statistical analysis. Grouped data were compared using
the paired two-tailed Students t test. A value of p < 0.05
was considered to be statistically significant.
Results
Suppression of ventricular arrhythmias. All 10 pa-
tients completed the study, and all the available data were
included in the analysis. The number of premature ventric-
ular complexes per hour for each of the patients over the
course ofthe five phases ofthe study are presented in Figures
1 and 2. The mean percent suppression of premature ven-
tricular complexes was 61.7% after encainide therapy com-
pared with 44.1 % after disopyramide. The decrease in ven-
tricular ectopic activity compared with baseline was
statistically significant for both encainide (p < 0.01) and
disopyrarnide therapy (p < 0.05). No significant differences
were noted between the baseline values and each of the two
placebo measurements preceding encainide and disopyr-
amide therapy.
During the encainide phase, 4 of the 10 patients showed
complete suppression of premature ventricular complexes
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Figure 2. Effects of disopyramide on premature ventricular com-
plex (PVC) frequency per hour (H) in 10 patients. Symbols as in
Figure I.
(defined as < 10 premature ventricular complexes per 24
hours), and 5 patients had less than 80% reduction in pre-
mature ventricular complexes with or without complete
suppression of episodes of ventricular tachycardia. One pa-
tient developed sustained ventricular tachycardia after 26
hours of treatment, despite a 92% suppression of premature
ventricular complexes (Fig. 3).
During the disopyramide phase, 3 of the 10 patients
exhibited greater than 80% suppression of premature ven-
tricular complexes, 6 patients had less than an 80% reduction
and in 1 patient, despite an 80% reduction, runs of ven-
tricular tachycardia documented during baseline ambulatory
monitoring were not suppressed (Fig. 3).
Figure 1. Effects of encainide on premature ventricular complex
(PVC) frequency per hour (H) in 10 patients. Open circles indicate
mean values; vertical bars show the standard error of the mean.
PVC/H
Figure 3. Percent variations in premature ventricular complex
(PVC) frequency with encainide and disopyramide. Efficacy is
assessed as an 80% decrease in the number of premature ventricular
complexes in comparison with that during the control period (0).
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T a ble 2. Variations in Electrocardiographic Interval Values During Encainide and Disopyramide
Therapy in Comparison With Values During the Control Period
Electrocardiographic Interval (ms)
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Control
Encainide
6%
Disopyramide
6%
PR
156 ± 23
207 ± 34
32.7*
162 ± 26
3.8t
QRS
86 ± II
112 ± 18
30.8*
94 ± 15
9.3t
QTc
423 ± 22
467± 46
1O.6t
439 ± 28
4.0t
Compared with control period values, *p < 0.001; tp < 0.01; tp = NS. Data are reported as mean values
± SD. 6 % = percent variation compared with control values.
Vital signs . No clinically significant changes in blood
pressure and heart rate were noted for either drug during
the course of the study compared with baseline.
Electrocardiographic interval changes (Table 2).
During the course of the study , encainide affected certain
electrocardiographic intervals. There was a mean increase
in the PR interval of 32.7 % (p < 0.001), a 30.8% increase
in QRS duration (p < 0.(01) and a 10.6% increase in the
QTc interval (p < 0.01). No significant changes were found
during the disopyramide phase . The QTc intervals were
increased up to 0.50 second in two patients (the baseline
values were 0.44 and 0.45 second, respectively) and up to
0.54 second in one patient (baseline value 0.43 second)
after encainide administration.
Exercise testing (Table 3). The frequency of premature
ventricular complexes and the occurrence of paired pre-
mature ventricular complexes and ventricular tachycardia
during exercise and during 5 minutes of recovery were com-
pared for the placebo, encainide and disopyramide treatment
periods. During the placebo phase, 9 of the 10 patients
exhibited premature ventricular complexes, the majority
having more than 10 during exercise and recovery periods.
After receiving encainide , only two patients manifested pre-
mature ventricular complexes, whereas after receiving di-
sopyramide six patients continued to have premature ven-
tricular complexes during exercise .
Drug concentrations. The mean ( ± SD) trough plasma
concentrations of encainide, and its metabolites (ODE and
MODE) were 19.6 ± 27.9, 138.7 ± 126.1 and 98.9 ±
35.6 ng/ml, respectively . Because the two metabolites are
active, an estimate was made by assuming equipotency , and
the antiarrhythmic activity was expressed as the sum of
T a ble 3. Exercise Treadmill Test: Frequency of Ventricular Arrhythmias During Placebo and
Active Drug Treatment Sequences
Placebo Encainide Disopyramide
Case PVC Pairs Runs PVC Pairs Runs PVC Pairs Runs
I +b 0 0 0 0 0 0 0 0
2 +b + + 0 0 0 +a + 0
3 + b 0 0 +b 0 0 + a 0 0
4 + a 0 0 0 0 0 + a 0 0
5 0 0 0 0 0 0 0 0 0
6 +b 0 0 0 0 0 + b 0 0
7 + b 0 0 0 0 0 0 0 0
8 +b 0 0 +b 0 0 +b 0 0
9 + a 0 0 0 0 0 0 0 0
10 +b + 0 ND ND ND +a 0 0
a = less than 10 premature ventricular complexes during exercise and during 5 minutes of recovery; b =
more than 10 premature ventricular complexes during exercise and during 5 minutes of recovery; ND = not
done; PVC = premature ventricular complexes; + = presence; 0 = absence.
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Figure 4. Relation between trough plasma levels
ofencainide and itsmetabolites (ODE, MODE) and
the antiarrhythmic efficacy on day 7 of treatment
in 10 patients. ENCA + ODE + MODE = the
sum of plasma levels of encainide, Q-demethyl en-
cainide and 3-methoxy-O-demethyl encainide. PVC
= premature ventricular complexes.
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encainide and two metabolites plasma concentrations. Ex-
cept for one patient, the highest values were usually ob-
served in patients who responded to therapy (Fig. 4). Im-
portantly, the patientwho failed to respondhad nodetectable
plasma levels of encainide or either metabolite. Because
normal concentrations were found I hour after a dose was
administered in the clinic, and considering the long serum
half-life of MODE, noncompliance seems likely. No rela-
tion could be established between plasma levels of diso-
pyramide and antiarrhythmic effect(Fig. 5). The mean plasma
concentration of disopyramide was 1.6 ± 0.8 jLg/ml.
Side effects. During encainide therapy, three patients
had mild headache, one patient had mild dizziness and one
patient had visual disturbance. After 26 hours of encainide
therapy, one patient developed sustained ventricular tachy-
cardia with a wide QRS interval (240 ms) and a heart rate
of 150 beats/min initiated by a couplet with a long interval
(520 ms). Treatment was discontinued in this patient and
cardioversion successfully terminated the ventricular tachy-
cardia. The next day, the patient had ventricular tachycardia
which was controlled by intravenous procainamide. This
patient had a previous myocardial infarction, a large left
ventricular aneurysm and a serum potassium level of 3.5
mEq/liter. It was difficult to assign a proarrhythmic role to
encainide because of these factors plus the previous occur-
rence of several episodes of sustained ventricular tachycar-
dia before encainide therapy. While taking disopyramide,
one patientcomplainedof dry mouth, one patient had a mild
headache and one patient suffered from moderate dysuria
which lessened after a 50% reduction of the dosage.
Discussion
Clinical efficacy. It is necessary to compare a new an-
tiarrhythmic agent with widely used and marketed antiar-
rhythmic drugs. We chose a double-blind, randomized
crossover protocol to compare encainide withdisopyramide.
Regardingthe design of this study, severalpoints are worthy
of note. To exclude patients whose premature ventricular
complexes were reduced spontaneously, patients were se-
lected after two 24 hour ambulatoryelectrocardiogramsthat
exhibited at least a mean of 60 premature ventricular com-
plexes per hour. A I week placebo interval between the
administration of the two antiarrhythmic drugs ensured com-
plete washoutof the effects of each drug. The I week period
of treatmentwithencainide wasjustifiedby pharmacokinetic
data. Kates et al. (8) have shown that quasi-steady state
serum concentrationsof the principal pharmacologically ac-
•
----------------------
Figure 5. Relation between trough plasma levels
of disopyramide (0150) and theantiarrhythmic ef-
ficacy on day 7 of treatment in nine patients. (For
technical reasons onedatum is notpresent) PVC =
premature ventricular complexes.
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tive metabolites are found at 2 to 3 days in the case of ODE
and at I week with MODE.
Our resultssuggestthat bothencainideanddisopyramide
wereefficaciousfor treatingchronicventriculararrhythmia.
Encainide was superior to disopyramide in suppression of
premature ventricular complexes (4 of 10 patients with en-
cainide versus 0 of 10 patients with disopyramide; p <
0.001). The mean percent suppression of premature ven-
tricular complexes compared with baseline values was greater
for encainide (61.7%) than for disopyramide (44. 1%) j but
the difference was not statistically significant.
In a double-blind, randomized crossover study compar-
ing encainide (200 mg/day) and quinidine (1,200 mg/day),
Sami et al. (3) reported that encainide was more effective
than quinidine in the treatment of ventricular ectopic activ-
ity. Consistent with our results, complete suppression of
premature ventricular complexes was noted in 44% of their
patients. In contrast, no patient demonstrated total suppres-
sion of premature ventricular complexes with quinidine.
Other studies have suggested that encainide is extremely
effective in suppressing chronic ventricular arrhythmia, and
the reported results (9) exceed the average suppression rate
of other antiarrhythmic drugs. Complete suppression of pre-
mature ventricular complexes was rare with quinidine (10, 11),
procainamide (11), disopyramide (12), tocainide (13,14)
and ethmozin (15,16), while flecainide (17,18) and lor-
cainide (19) exhibited degrees of suppression of ventricular
ectopic activity comparable with those obtained with en-
cainide. In addition, encainide was found an effective, well
tolerated drug for the treatment of drug-refractory ventric-
ular tachycardia (20). In our study, encainide significantly
prolonged the PR, QRS and QTc intervals. These prolon-
gations were seen as a manisfestation of the pharmacology
of encainide and its metabolites.
Side effects. Encainide caused minor side effects, but
discontinuation of therapy was not required except in one
patient who had ventricular tachycardia. In this patient,
encainide was suspected to initiate the tachycardia. The
potential of all antiarrhythmic agents to provoke or aggra-
vate ventricular arrhythmia is widely recognized. In a recent
retrospective study, Velebit et al. (21) determined the fre-
quency of aggravation of arrhythmia with nine antiar-
rhythmic drugs (quinidine, procainamide, disopyramide,
propranolol, metoprolol, aprindine, mexiletine, tocainide
and pindolol). The frequency for a specific drug ranged from
5.9 to 15.8%. According to Winkle et al. (20), the risk of
encainide-induced ventricular tachycardia was II % in 90
patients receiving the drug for recurrent sustained ventric-
ular tachycardia or ventricular fibrillation, or both, and 2.2%
in 47 patients receiving the drug for chronic complex ven-
tricular ectopic activity.
A drug-induced arrhythmic aggravation is not yet pre-
dictable, although several risk factors (namely, the presence
of ischemic heart disease, ventricular dysfunction, type of
ventricular arrhythmia and lack of response to other antiar-
rhythmic agents) have been tentatively identified. Cohen et
al. (22) showed that patients with ventricular tachycardia
had a significantly larger aneurysm and a higher prevalence
of septal akinesia or dyskinesia. Rochemaure et al. (23) also
found that 28% of a group of 39 patients with a large an-
eurysm had ventricular tachycardia, whereas only 2% of a
group of 48 patients with a small aneurysm developed ven-
tricular tachycardia.
In agreement with these findings, our patient who had a
possible encainide-induced ventricular tachycardia had a large
aneurysm. Moreover, in this patient, a blood sample was
drawn 2 hours before the episode of ventricular tachycardia
and just before the last intake of the drug. ODE metabolite
concentration was 308 ng/rnl. Several studies have dem-
onstrated that ODE and MODE metabolites account for
some of encainide' s toxicity and efficacy. In a recent report,
Dawson et al. (24) showed that concentrations of ODE
greater than 300 ng/ml can significantly lower the ventricular
fibrillation threshold in an ischemic canine model. None-
theless, higher serum concentrations of ODE are found in
patients not exhibiting a drug-induced aggravation of ar-
rhythmia. One could speculate that three factors contributed
to the worsening of arrhythmia in our patient: ventricular
aneurysm, hypokalemia and a high concentration of ODE.
During disopyramide treatment, three of our patients com-
plained of side effects that did not require withdrawal of
the drug.
Conclusions. Encainide is a highly effective antiar-
rhythmic agent. It appears to be superior to disopyramide
for complete suppression of premature ventricular com-
plexes. Although encainide is a well tolerated drug, it may
exacerbate cardiac arrhythmias in some patients.
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